<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02690974</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696BCA02</org_study_id>
    <nct_id>NCT02690974</nct_id>
  </id_info>
  <brief_title>Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting</brief_title>
  <acronym>PARASAIL</acronym>
  <official_title>Prospective, Multi-center, Open lAbel, Post-appRovAl Study AImed at Characterizing the Use of LCZ696 at 97.2 mg Sacubitril / 102.8 mg Valsartan Bid in Patients With HFrEF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study will be to describe the tolerability of treatment with the
      optimal dose of LCZ696 (97.2 mg sacubitril / 102.8 mg valsartan bid), over six (6) months, in
      patients with heart failure with reduced ejection fraction (HFrEF) in Canada.

      The study will also describe the overall tolerability, effectiveness and safety of LCZ696 for
      the management of HFrEF over 12 months of treatment, as well as describe the patterns of
      LCZ696 up and down dose titrations occurring during the management of patients with HFrEF.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 8, 2016</start_date>
  <completion_date type="Actual">November 29, 2017</completion_date>
  <primary_completion_date type="Actual">June 7, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who tolerated LCZ696 at the dose of 97.2 mg sacubitril / 102.8 mg valsartan bid at month 6</measure>
    <time_frame>at month 6</time_frame>
    <description>Tolerability is defined as patients who on LCZ696 at the dose of 97.2 mg sacubitril / 102.8 mg valsartan twice daily (bid), but did not experience down titration or treatment discontinuation because of adverse events while on this dose at month 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who tolerated LCZ696 at the dose of 97.2 mg sacubitril / 102.8 mg valsartan bid at Month 12</measure>
    <time_frame>at month 12</time_frame>
    <description>Tolerability is defined as patients who on LCZ696 at the dose of 97.2 mg sacubitril / 102.8 mg valsartan twice daily (bid), but did not experience down titration or treatment discontinuation because of adverse events while on this dose at month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients on LCZ696 requiring down-titration after reaching the 97.2 mg sacubitril / 102.8 mg valsartan dose</measure>
    <time_frame>at Month 6 and Month 12 visits</time_frame>
    <description>To evaluate the impact of the titration scheme on the tolerability of patients maintained on LCZ696 97.2 mg sacubitril / 102.8 mg valsartan bid at 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of down-titration changes from 97.2 mg sacubitril / 102.8 mg valsartan</measure>
    <time_frame>at Month 6 and Month 12 visits</time_frame>
    <description>To evaluate the impact of the titration scheme on the tolerability of patients maintained on LCZ696 97.2 mg sacubitril / 102.8 mg valsartan bid at 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Six Minute Walk Test</measure>
    <time_frame>Baseline, Month 6 and Month 12</time_frame>
    <description>To describe the impact of LCZ696 on functional exercise capacity, as measured by the Six Minute Walk Test, at 6 and 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to LCZ696 up-titration to 97.2 mg sacubitril / 102.8 mg valsartan bid)</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>To describe the time of up-titration for each dose (24.3 mg sacubitril / 25.7 mg valsartan bid and 48.6 mg sacubitril / 51.4 mg valsartan bid) of LCZ696.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration time in days during the up-titration for each dose (24.3 mg sacubitril / 25.7 mg valsartan bid and 48.6 mg sacubitril / 51.4 mg valsartan bid) of LCZ696</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>To describe the time of up-titration for each dose (24.3 mg sacubitril / 25.7 mg valsartan bid and 48.6 mg sacubitril / 51.4 mg valsartan bid) of LCZ696</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients on guideline recommended dose of beta-blockers and MRAs</measure>
    <time_frame>Baseline, Month 6 and Month 12</time_frame>
    <description>To describe the adherence to guideline recommended dosing of beta-blockers and MRAs at 6 and 12 months of treatment with LCZ696</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">304</enrollment>
  <condition>Hearth Failure With Reduced Ejection Fraction (HFrEF)</condition>
  <arm_group>
    <arm_group_label>LCZ696 (sacubitril / valsartan)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients will be initiated on LCZ696 at 24.3 mg sacubitril / 25.7 mg valsartan that can be up-titrated to LCZ696 48.6 mg sacubitril / 51.4 mg valsartan bid after 2-4 weeks and then up-titrated again to 97.2 mg sacubitril / 102.8 mg valsartan bid after another 2 - 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696 (sacubitril/valsartan)</intervention_name>
    <description>All patients will be treated with the LCZ696 (sacubitril and valsartan) tablets</description>
    <arm_group_label>LCZ696 (sacubitril / valsartan)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent must be obtained before any assessment is performed.

          2. Age ≥ 18 years and ≤ 80 years.

          3. Males or females.

          4. Diagnosis of Heart Failure NYHA class II-III.

          5. Diagnosis of Heart Failure with reduced Ejection Fraction (LVEF &lt; 40%) and NYHA class
             II or III.

          6. Stable on any dose of ACEI or ARB prior to enrolment in the study

          7. Stable on any dose of a beta-blocker prior to enrolment in the study.

          8. Eligible for treatment with LCZ696 as per Canadian product monograph.

          9. Treated as an outpatient.

         10. Signed an informed consent agreeing to participate in the study.

        Exclusion Criteria:

          1. Symptomatic hypotension and/or a SBP &lt; 100 mmHg at baseline visit.

          2. Estimated GFR &lt; 30 mL/min/1.73m^2 as measured by the simplified Modification of Diet
             in Renal Disease (MDRD) formula at baseline visit.

          3. Known history of angioedema related to previous ACEI or ARBs therapy, or history of
             hereditary or idiopathic angioedema.

          4. Requirement of concomitant treatment with both ACEIs and ARBs.

          5. Concurrent participation in other clinical trials or receiving other investigational
             drugs within 30 days of enrollment.

          6. Hypersensitivity to the active substances, sacubitril or valsartan, or to any of the
             excipients.

          7. Concomitant use of aliskiren-containing drugs in patients with diabetes mellitus (type
             1 or type 2) or moderate to severe renal impairment (GFR &lt;60ml/min/1.73m^2).

          8. History of hypersensitivity to any of the study drugs or to drugs of similar chemical
             classes.

          9. History of malignancy of any organ system (other than localized basal cell carcinoma
             of the skin), treated or untreated, within the past 5 years, regardless of whether
             there is evidence of local recurrence or metastases.

         10. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test.

         11. Women of childbearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using effective methods of contraception during
             dosing of study treatment. Effective contraception methods are described in the
             protocol.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 3W4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 2Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1G 1A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7M 4Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 6V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5K 2L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 8C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1E 5E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1P 2V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 3B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6R 1B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2T 0C1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Weston</city>
        <state>Ontario</state>
        <zip>M9N 1W4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Joliette</city>
        <state>Quebec</state>
        <zip>J6E 6J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 3Y7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St-Jean-sur-Richelieu</city>
        <state>Quebec</state>
        <zip>J3A 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Terrebonne</city>
        <state>Quebec</state>
        <zip>J6V 2H2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brossard</city>
        <zip>J4Z 2K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <zip>L8L 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>GIV 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St-Lambert</city>
        <zip>J4P 2J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2016</study_first_submitted>
  <study_first_submitted_qc>February 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HFrEF,</keyword>
  <keyword>ACEi,</keyword>
  <keyword>ACE inhibitor,</keyword>
  <keyword>ARBs,</keyword>
  <keyword>systolic heart failure,</keyword>
  <keyword>chronic heart failure,</keyword>
  <keyword>CHF,</keyword>
  <keyword>reduced EF,</keyword>
  <keyword>Ejection Fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

